» Articles » PMID: 26741694

Toll-Like Receptor 4 Is Essential in the Development of Abdominal Aortic Aneurysm

Overview
Journal PLoS One
Date 2016 Jan 8
PMID 26741694
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptor (TLR) family plays a key role in innate immunity and various inflammatory responses. TLR4, one of the well-characterized pattern-recognition receptors, can be activated by endogenous damage-associated molecular pattern molecules such as high mobility group box 1 (HMGB1) to sustain sterile inflammation. Evidence suggested that blockade of TLR4 signaling may confer protection against abdominal aortic aneurysm (AAA). Herein we aimed to obtain further insight into the mechanism by which TLR4 might promote aneurysm formation. Characterization of the CaCl2-induced AAA model in mice revealed that upregulation of TLR4 expression, localized predominantly to vascular smooth muscle cells (VSMCs), was followed by a late decline during a 28-day period of AAA development. In vitro, TLR4 expression was increased in VSMCs treated with HMGB1. Knockdown of TLR4 by siRNA attenuated HMGB1-enhanced production of proinflammatory cytokines, specifically interleukin-6 and monocyte chemoattractant protein-1 (MCP-1), and matrix-degrading matrix metalloproteinase (MMP)-2 from VSMCs. In vivo, two different strains of TLR4-deficient (C57BL/10ScNJ and C3H/HeJ) mice were resistant to CaCl2-induced AAA formation compared to their respective controls (C57BL/10ScSnJ and C3H/HeN). Knockout of TLR4 reduced interleukin-6 and MCP-1 levels and HMGB1 expression, attenuated macrophage accumulation, and eventually suppressed MMP production, elastin destruction and VSMC loss. Finally, human AAA exhibited higher TLR4 expression that was localized to VSMCs. These data suggest that TLR4 signaling contributes to AAA formation by promoting a proinflammatory status of VSMCs and by inducing proteinase release from VSMCs during aneurysm initiation and development.

Citing Articles

Myeloid-specific knockout of Notch-1 inhibits MyD88- and TRIF-mediated TLR signaling pathways by regulating oxidative stress-SHP2 axis, thus restraining aneurysm progression.

Li Y, Guo A, Liu J, Tang L, Su L, Liu Z Aging (Albany NY). 2024; 16(2):1182-1191.

PMID: 38284891 PMC: 10866402. DOI: 10.18632/aging.205392.


Soluble CD93 lectin-like domain sequesters HMGB1 to ameliorate inflammatory diseases.

Huang S, Kuo C, Shiao S, Shen C, Lee F, Chang B Theranostics. 2023; 13(12):4059-4078.

PMID: 37554277 PMC: 10405849. DOI: 10.7150/thno.84935.


Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review.

Panzer B, Kopp C, Neumayer C, Koppensteiner R, Jozkowicz A, Poledniczek M Cells. 2023; 12(14).

PMID: 37508529 PMC: 10377790. DOI: 10.3390/cells12141865.


Treatment With Small Molecule Inhibitors of Advanced Glycation End-Products Formation and Advanced Glycation End-Products-Mediated Collagen Cross-Linking Promotes Experimental Aortic Aneurysm Progression in Diabetic Mice.

Li Y, Zheng X, Guo J, Samura M, Ge Y, Zhao S J Am Heart Assoc. 2023; 12(10):e028081.

PMID: 37158066 PMC: 10227285. DOI: 10.1161/JAHA.122.028081.


Dexmedetomidine protects cells from Angiotensin II-induced smooth muscle cell phenotype switch and endothelial cell dysfunction.

Dai M, Zhu X, Zeng S, Liu Q, Hu R, Huang L Cell Cycle. 2022; 22(4):450-463.

PMID: 36196460 PMC: 9879174. DOI: 10.1080/15384101.2022.2124489.


References
1.
Qin Y, Cao X, Yang Y, Shi G . Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. Future Cardiol. 2012; 9(1):89-103. PMC: 3568657. DOI: 10.2217/fca.12.71. View

2.
Satoh K, Nigro P, Matoba T, ODell M, Cui Z, Shi X . Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009; 15(6):649-56. PMC: 2704983. DOI: 10.1038/nm.1958. View

3.
Qin Z, Bagley J, Sukhova G, Baur W, Park H, Beasley D . Angiotensin II-induced TLR4 mediated abdominal aortic aneurysm in apolipoprotein E knockout mice is dependent on STAT3. J Mol Cell Cardiol. 2015; 87:160-70. DOI: 10.1016/j.yjmcc.2015.08.014. View

4.
Zhang F, Kent K, Yamanouchi D, Zhang Y, Kato K, Tsai S . Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg. 2009; 250(3):416-23. PMC: 2921961. DOI: 10.1097/SLA.0b013e3181b41a18. View

5.
Shimizu K, Mitchell R, Libby P . Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006; 26(5):987-94. DOI: 10.1161/01.ATV.0000214999.12921.4f. View